Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATL 101 - Telix Pharmaceuticals

Drug Profile

ATL 101 - Telix Pharmaceuticals

Alternative Names: 177Lu-J591; 90Y-J591; Anti-PSMA monoclonal antibody J591; Anti-PSMA-monoclonal-antibody-J-591-Lu-177; huJ 591; J 591; J-591-Lu-177; Lu-177-J591; Lu-177-MLN-591; Lutetium-177-labelled anti-PSMA monoclonal antibody J591; Lutetium-177-labelled-J-591; Lutetium-177labelled-MLN-591; MLN 591RL; MLN591; Monoclonal antibody J591; Monoclonal-antibody-J-591-Lu-177; muJ591; Radiolabelled J591; Radiolabelled MLN591

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell University
  • Developer BZL Biologics; Weill Cornell Medical College
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Prostate cancer
  • No development reported Solid tumours

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 28 Feb 2019 No recent reports of development identified for phase-I development in Prostate-cancer(Neoadjuvant therapy) in USA (IV, Infusion)
  • 10 Sep 2018 ATLAB Pharma has been acquired by Telix Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top